Elanco shareholders elect two directors despite majority against; stock plans approved

Proposal 4. The shareholders approved the Amended and Restated Elanco Animal Health Incorporated Employee Stock Purchase Plan, by the votes set forth in the table below. For Against Abstain Broker Non-Votes 434,472,778 566,174 762,214 13,179,219

Proposal 3. The shareholders approved, by non-binding vote, the compensation of Elanco’s named executive officers, by the votes set forth in the table below. For Against Abstain Broker Non-Votes 351,081,265 82,468,671 2,251,230 13,179,219

Proposal 1. Election of Directors. All of the nominees nominated by the Board for director were elected to serve for a three-year term ending at the 2026 annual meeting of shareholders and until their respective successors are elected and qualified, by the votes set forth in the table below. Nominee For Against Abstain Broker Non-Votes Michael J. Harrington 259,613,361 175,243,353 944,452 13,179,219 R. David Hoover 125,220,272 309,651,471 929,423 13,179,219 Deborah T. Kochevar 164,946,577 269,918,338 936,251 13,179,219 Kirk P. McDonald 267,112,564 167,731,710 956,892 13,179,219

Proposal 5. The shareholders approved the Amended and Restated 2018 Elanco Animal Health Incorporated Stock Plan, by the votes set forth in the table below. For Against Abstain Broker Non-Votes 417,966,666 17,058,140 776,360 13,179,219

Proposal 2. The shareholders ratified the appointment of Ernst & Young LLP as Elanco’s independent registered public accounting firm for 2023, by the votes set forth in the table below. For Against Abstain 447,693,969 524,302 762,114